TITLE

SNDA FILED FOR XENICAL AS TYPE 2 DIABETES TREATMENT OPTION

PUB. DATE
May 2001
SOURCE
Worldwide Biotech;May2001, Vol. 13 Issue 5, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Roche has announced that a supplemental New Drug Application has been submitted to the United States Food and Drug Administration for Xenical.
ACCESSION #
4425596

 

Related Articles

  • THREE FOR FREE. Breitstein, Joanna // Pharmaceutical Executive;Nov2001, Vol. 21 Issue 11, p78 

    Presents information on the incentive program launched by Roche company for its weight loss drug Xenical. Details on the incentive program for customers that buy Xenical; Requirements for participation in the program; Recommendation of the United States National Institutes of Health to...

  • Xenical says goodbye to confusing ads. Hayes, Tara // B&T Weekly;3/3/2006, Vol. 56 Issue 2554, p3 

    The article reports on the advertising campaign set by Roche to produce branded advertising for its Xenical fat-busting product. This initiative was made due to some advertisements, which had been mistaken for community service announcements. In 2004, legislation prevented the company from...

  • Roche Pharmaceuticals.  // Improving Growth & Profits: Roche Pharmaceuticals Case Study;2005, p127 

    The article highlights the international health care company Roche Pharmaceuticals in Nutley, New Jersey. Roche's operations have expanded from pharmaceuticals to diagnostics to the primary care markets. It has developed Xenical for obesity and Taminflu for influenza. Roche has created a...

  • FDA Actions.  // Primary Care Reports;Mar2007, Vol. 13 Issue 3, p2 

    This article offers news briefs related to U.S. Food and Drug Administration (FDA) actions. The agency has warned against unsupervised use of topical anesthetic products for cosmetic procedures after receiving multiple reports of adverse events associated with patients applying excess amounts of...

  • pharma In Brief.  // Chemical Market Reporter;5/28/2001, Vol. 259 Issue 22, p7 

    Presents updates on the pharmaceutical industry as of May 2001. Price increase on choline chloride that will be implemented by Chinook Group Ltd.; Insulin analog launched by the Aventis company; Application of the Roche company to add a new indication to the Xenical prescription drug.

  • Coming your way.  // Pulse;8/13/2005, Vol. 65 Issue 32, p8 

    Presents news items related to the general practice, which were published in newspapers and online periodicals in Great Britain. Cambridge-based company Acambis' development of a potentially breakthrough influenza vaccine that could offer permanent protection and might also protect against...

  • Statins on script, but Xenical to change. Hill, Susie // New Zealand Doctor;7/14/2004, p19 

    Reports on the decision of the Medicines Classification Committee to reject the proposal from HeartCare Plus to reclassify simvastatin as a pharmacy-only medicine in New Zealand in 2004. Reasons behind the decision; Status of the proposal from Roche to reclassify orlistat as a pharmacist-only...

  • REPORTER'S NOTEBOOK.  // Drug Store News;1/19/2004, Vol. 26 Issue 1, p21 

    Reports developments related to the pharmaceutical industry in the U.S. as of January 2004. Extension of market exclusivity to Bayer Pharmaceuticals Corp. for the antibiotic Cipro; Approval given to Roche for the use of prescription weight loss medication Xenical in treating obesity among...

  • Roche moves OTC work in central Europe to Saatchi.  // Advertising Age's Euromarketing;8/6/96, Vol. 9 Issue 47, p1 

    Reports that Roche Consumer Health of eastern Europe has awarded Saatchi & Saatchi the advertising accounts for its Supradyn, Rennie, Aspro and Bepanthene brands. Value of the account.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics